Blue Earth Diagnostics Ltd.

The Oxford Science Park, Magdalen Centre
Robert Robinson Avenue, Unit F14
Oxford, OX4 4GA
England
Phone:
+44.(0)1865.784.186
Fax:
+44.(0)1865.784.004
http://www.blueearthdiagnostics.com/
Product Categories:

RELATED CONTENT

177Lutetium-labeled radiohybrid (rh) Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is an optimized, next generation therapeutic radiopharmaceutical
News | SNMMI

Blue Earth Therapeutics Announces Results of Early Clinical and ...

June 29, 2023 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time June 29, 2023
Read more
POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023
News | Prostate Cancer

Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens ...

June 21, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 21, 2023
Read more
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) ...

May 30, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 30, 2023
Read more
The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy
News | PET Imaging

Blue Earth Diagnostics Highlights Presentations on Axumin ...

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
Read more
NorthStar will provide Clovis with its environmentally preferred, high purity non-carrier-added (n.c.a.) Ac-225
News | PET Imaging

Independent Clinical Studies Published Regarding Performance of Axumin ...

July 20, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 20, 2022
Read more
News | PET Imaging

Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE ...

June 8, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 08, 2022
Read more
Oral presentation based on Late-breaking Abstract featured at American Urological Association’s 2022 Annual Meeting (AUA2022)
News | Radiopharmaceuticals and Tracers

Blue Earth Diagnostics Announces Additional Results from Phase 3 ...

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
Read more
Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug Application (IND) application for 177Lu-rhPSMA-10.1.
News | Prostate Cancer

Blue Earth Therapeutics Announces U.S. FDA Clearance for ...

April 19, 2022 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time April 19, 2022
Read more
18F-rhPSMA-7.3 PET Photo courtesy of Blue Earth Diagnostics. General use: This 18F-rhPSMA-7.3 PET image shows prostate cancer spread beyond the prostate region. Technical use: This 18F-rhPSMA-7.3 PET image shows detection of recurrent prostate cancer in several retroperitoneal lymph nodes, as indicated by the green arrows.
News | Prostate Cancer

Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT ...

February 18, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 18, 2022
Read more
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced presentations on Axumin (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
News | PET Imaging

Blue Earth Diagnostics Highlights Presentations on Axumin ...

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2021
Read more
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now